Established and emerging cardiovascular magnetic resonance techniques for prognostication and guiding therapy in heart failure

References

• Djousse L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 302(4), 394–400 (2009).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24), 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am. J. Cardiol. 101(7), 1016–1022 (2008).
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347(18), 1397–1402 (2002).
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1), e6–e245 (2013).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128, e240–e327 (2013).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14(8), 803–869 (2012).
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J. Am. Coll. Cardiol. 54(15), 1407–1424 (2009).
   PubMed Web of Science ®Google Scholar
• Bruder O, Schneider S, Nothnagel D et al. EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. J. Am. Coll. Cardiol. 54(15), 1457–1466 (2009).
   Google Scholar
• Larkman DJ, Nunes RG. Parallel magnetic resonance imaging. Phys. Med. Biol. 52(7), R15–R55 (2007).
   Google Scholar
• Utz JA, Herfkens RJ, Heinsimer JA et al. Cine MR determination of left ventricular ejection fraction. AJR Am. J. Roentgenol. 148(5), 839–843 (1987).
   Google Scholar
• Grothues F, Smith GC, Moon JC et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am. J. Cardiol. 90(1), 29–34 (2002).
   PubMed Web of Science ®Google Scholar
• Gradman A, Deedwania P, Cody R et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J. Am. Coll. Cardiol. 14(3), 564–570; discussion 571–562 (1989).
   PubMed Web of Science ®Google Scholar
• Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am. J. Cardiol. 54(1), 147–152 (1984).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Anavekar N, Skali H et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112(24), 3738–3744 (2005).
   PubMed Web of Science ®Google Scholar
• Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12), 2660–2667 (1997).
   PubMed Web of Science ®Google Scholar
• Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog. Cardiovasc. Dis. 54(2), 86–96 (2011).
   Google Scholar
• Valsangiacomo Buechel ER, Mertens LL. Imaging the right heart: the use of integrated multimodality imaging. Eur. Heart J. 33(8), 949–960 (2012).
   PubMed Web of Science ®Google Scholar
• Larose E, Ganz P, Reynolds HG et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J. Am. Coll. Cardiol. 49(8), 855–862 (2007).
   PubMed Web of Science ®Google Scholar
• Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 12, 65 (2010).
   Google Scholar
• Gulati A, Ismail TF, Jabbour A et al. Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur. J. Heart Fail. 15(6), 660–670 (2013).
   Google Scholar
• Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur. Heart J. 26(15), 1461–1474 (2005).
   PubMed Web of Science ®Google Scholar
• Zemrak F, Petersen SE. Late gadolinium enhancement CMR predicts adverse cardiovascular outcomes and mortality in patients with coronary artery disease: systematic review and meta-analysis. Prog. Cardiovasc. Dis. 54(3), 215–229 (2011).
   Google Scholar
• Kwong RY, Chan AK, Brown KA et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113(23), 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Steel K, Broderick R, Gandla V et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 120(14), 1390–1400 (2009).
   PubMedGoogle Scholar
• Kwong RY, Sattar H, Wu H et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 118(10), 1011–1020 (2008).
   PubMed Web of Science ®Google Scholar
• Kelle S, Roes SD, Klein C et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J. Am. Coll. Cardiol. 54(19), 1770–1777 (2009).
   PubMed Web of Science ®Google Scholar
• Kwon DH, Halley CM, Carrigan TP et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc. Imaging 2(1), 34–44 (2009).
   Google Scholar
• Yokota H, Heidary S, Katikireddy CK et al. Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy. J. Cardiovasc. Magn. Reson. 10, 17 (2008).
   Google Scholar
• Schmidt A, Azevedo CF, Cheng A et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115(15), 2006–2014 (2007).
   PubMed Web of Science ®Google Scholar
• Yan AT, Shayne AJ, Brown KA et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114(1), 32–39 (2006).
   PubMed Web of Science ®Google Scholar
• Wu KC, Zerhouni EA, Judd RM et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97(8), 765–772 (1998).
   PubMed Web of Science ®Google Scholar
• Gerber BL, Rochitte CE, Melin JA et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 101(23), 2734–2741 (2000).
   PubMed Web of Science ®Google Scholar
• McCrohon JA, Moon JC, Prasad SK et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108(1), 54–59 (2003).
   PubMed Web of Science ®Google Scholar
• Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 48(10), 1977–1985 (2006).
   PubMed Web of Science ®Google Scholar
• Gulati A, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309(9), 896–908 (2013).
   PubMed Web of Science ®Google Scholar
• Kubanek M, Sramko M, Maluskova J et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J. Am. Coll. Cardiol. 61(1), 54–63 (2013).
   Google Scholar
• Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109(10), 1250–1258 (2004).
   PubMed Web of Science ®Google Scholar
• De Cobelli F, Pieroni M, Esposito A et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J. Am. Coll. Cardiol. 47(8), 1649–1654 (2006).
   Google Scholar
• Abdel-Aty H, Boye P, Zagrosek A et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J. Am. Coll. Cardiol. 45(11), 1815–1822 (2005).
   PubMed Web of Science ®Google Scholar
• Grun S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J. Am. Coll. Cardiol. 59(18), 1604–1615 (2012).
   PubMed Web of Science ®Google Scholar
• Choudhury L, Mahrholdt H, Wagner A et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 40(12), 2156–2164 (2002).
   PubMed Web of Science ®Google Scholar
• Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 35(1), 36–44 (2000).
   Google Scholar
• Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 41(9), 1561–1567 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi S, Raineri C, De Ferrari GM et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur. Heart J. 30(16), 2003–2010 (2009).
   Google Scholar
• O'Hanlon R, Grasso A, Roughton M et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56(11), 867–874 (2010).
   PubMed Web of Science ®Google Scholar
• Rubinshtein R, Glockner JF, Ommen SR et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ. Heart Fail. 3(1), 51–58 (2010).
   PubMed Web of Science ®Google Scholar
• Maron MS, Appelbaum E, Harrigan CJ et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ. Heart Fail. 1(3), 184–191 (2008).
   PubMed Web of Science ®Google Scholar
• Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56(11), 875–887 (2010).
   PubMed Web of Science ®Google Scholar
• Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58(6), 1204–1211 (1978).
   PubMed Web of Science ®Google Scholar
• Patel MR, Cawley PJ, Heitner JF et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 120(20), 1969–1977 (2009).
   PubMed Web of Science ®Google Scholar
• Greulich S, Deluigi CC, Gloekler S et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc. Imaging 6(4), 501–511 (2013).
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc. Imaging 3(2), 155–164 (2010).
   PubMed Web of Science ®Google Scholar
• Austin BA, Tang WH, Rodriguez ER et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc. Imaging 2(12), 1369–1377 (2009).
   PubMed Web of Science ®Google Scholar
• Tandri H, Saranathan M, Rodriguez ER et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J. Am. Coll. Cardiol. 45(1), 98–103 (2005).
   Google Scholar
• Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn. Reson. Med. 52(1), 141–146 (2004).
   PubMed Web of Science ®Google Scholar
• Verhaert D, Thavendiranathan P, Giri S et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc. Imaging 4(3), 269–278 (2011).
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Phrommintikul A et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52(19), 1574–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Flett AS, Hayward MP, Ashworth MT et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122(2), 138–144 (2010).
   PubMed Web of Science ®Google Scholar
• Dass S, Suttie JJ, Piechnik SK et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ. Cardiovasc. Imaging 5(6), 726–733 (2012).
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Voigt T, Chen Z et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc. Imaging 6(4), 475–484 (2013).
   PubMed Web of Science ®Google Scholar
• Sado DM, Flett AS, Banypersad SM et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98(19), 1436–1441 (2012).
   PubMed Web of Science ®Google Scholar
• Ho CY, Abbasi SA, Neilan TG et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ. Cardiovasc. Imaging 6(3), 415–422 (2013).
   PubMed Web of Science ®Google Scholar
• Fontana M, Barison A, Botto N et al. CMR-verified interstitial myocardial fibrosis as a marker of subclinical cardiac involvement in LMNA mutation carriers. JACC Cardiovasc. Imaging 6(1), 124–126 (2013).
   PubMed Web of Science ®Google Scholar
• Thompson RB, Chow K, Khan A et al. T1 mapping with CMR is highly sensitive for Fabry disease independent of hypertrophy and gender. Circ. Cardiovasc. Imaging 6(5), 637–645 (2013).
   PubMed Web of Science ®Google Scholar
• Sado DM, White SK, Piechnik SK et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 6(3), 392–398 (2013).
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc. Imaging 6(4), 488–497 (2013).
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Sado DM, Flett AS et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ. Cardiovasc. Imaging 6(1), 34–39 (2013).
   PubMed Web of Science ®Google Scholar
• Rao AD, Shah RV, Garg R et al. Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. Am. J. Cardiol. 112(1), 73–78 (2013).
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler KM, Kang IA et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur. Heart J. (2013) (Epub ahead of print).
   Google Scholar
• Wong TC, Piehler K, Meier CG et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126(10), 1206–1216 (2012).
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22(23), 2171–2179 (2001).
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Markussis V, Kaklamanis L et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur. J. Haematol. 75(3), 241–247 (2005).
   Google Scholar
• Holloway CJ, Suttie J, Dass S, Neubauer S. Clinical cardiac magnetic resonance spectroscopy. Prog. Cardiovasc. Dis. 54(3), 320–327 (2011).
   PubMed Web of Science ®Google Scholar
• Neubauer S. The failing heart – an engine out of fuel. N. Engl. J. Med. 356(11), 1140–1151 (2007).
   PubMed Web of Science ®Google Scholar
• Neubauer S, Horn M, Cramer M et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7), 2190–2196 (1997).
   PubMed Web of Science ®Google Scholar
• Rayatzadeh H, Patel SJ, Hauser TH et al. Volumetric left ventricular ejection fraction is superior to 2-dimensional echocardiography for risk stratification of patients for primary prevention implantable cardioverter-defibrillator implantation. Am. J. Cardiol. 111(8), 1175–1179 (2013).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352(3), 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346(12), 877–883 (2002).
   PubMed Web of Science ®Google Scholar
• Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J. Am. Coll. Cardiol. 44(11), 2166–2172 (2004).
   PubMed Web of Science ®Google Scholar
• Wu KC, Weiss RG, Thiemann DR et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 51(25), 2414–2421 (2008).
   PubMed Web of Science ®Google Scholar
• Roes SD, Borleffs CJ, van der Geest RJ et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ. Cardiovasc. Imaging 2(3), 183–190 (2009).
   PubMed Web of Science ®Google Scholar
• Boye P, Abdel-Aty H, Zacharzowsky U et al. Prediction of life-threatening arrhythmic events in patients with chronic myocardial infarction by contrast-enhanced CMR. JACC Cardiovasc. Imaging 4(8), 871–879 (2011).
   Google Scholar
• Bello D, Fieno DS, Kim RJ et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J. Am. Coll. Cardiol. 45(7), 1104–1108 (2005).
   Google Scholar
• Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Lardo AC, Abraham TP, Kass DA. Magnetic resonance imaging assessment of ventricular dyssynchrony: current and emerging concepts. J. Am. Coll. Cardiol. 46(12), 2223–2228 (2005).
   Google Scholar
• Bilchick KC, Dimaano V, Wu KC et al. Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc. Imaging 1(5), 561–568 (2008).
   Google Scholar
• Leyva F, Foley PW, Chalil S et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 13, 29 (2011).
   Google Scholar
• Eighteen-year follow-up in the veterans affairs cooperative study of coronary artery bypass surgery for stable angina. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Circulation 86(1), 121–130 (1992).
   PubMed Web of Science ®Google Scholar
• Caracciolo EA, Davis KB, Sopko G et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 91(9), 2335–2344 (1995).
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med. 364(17), 1607–1616 (2011).
   PubMed Web of Science ®Google Scholar
• Bonow RO, Maurer G, Lee KL et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N. Engl. J. Med. 364(17), 1617–1625 (2011).
   PubMed Web of Science ®Google Scholar
• Kim RJ, Wu E, Rafael A et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N. Engl. J. Med. 343(20), 1445–1453 (2000).
   PubMed Web of Science ®Google Scholar
• Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc. Imaging 5(5), 494–508 (2012).
   Google Scholar
• Baer FM, Theissen P, Schneider CA et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J. Am. Coll. Cardiol. 31(5), 1040–1048 (1998).
   PubMed Web of Science ®Google Scholar
• Knuesel PR, Nanz D, Wyss C et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 108(9), 1095–1100 (2003).
   Google Scholar
• Shah DJ, Kim HW, James O et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA 309(9), 909–918 (2013).
   Google Scholar
• Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107(18), 2290–2293 (2003).
   PubMed Web of Science ®Google Scholar
• Chugh AR, Beache GM, Loughran JH et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 126(11 Suppl. 1), S54–S64 (2012).
   PubMed Web of Science ®Google Scholar